Last reviewed · How we verify

Rasagiline mesylate with Requip

Teva Neuroscience, Inc. · FDA-approved active Small molecule

Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while ropinirole (Requip) is a dopamine D2/D3 receptor agonist, together enhancing dopaminergic signaling for Parkinson's disease management.

Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while ropinirole (Requip) is a dopamine D2/D3 receptor agonist, together enhancing dopaminergic signaling for Parkinson's disease management. Used for Parkinson's disease (motor symptom management).

At a glance

Generic nameRasagiline mesylate with Requip
SponsorTeva Neuroscience, Inc.
Drug classMAO-B inhibitor combined with dopamine receptor agonist
TargetMAO-B and dopamine D2/D3 receptors
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Rasagiline irreversibly inhibits MAO-B, the enzyme responsible for dopamine breakdown in the brain, thereby increasing dopamine availability. Ropinirole directly stimulates dopamine D2 and D3 receptors on striatal neurons. Together, these complementary mechanisms enhance dopaminergic neurotransmission to alleviate motor symptoms of Parkinson's disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: